Higher dose tested in fight against returning breast cancer

NCT ID NCT00099437

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study tested whether a higher dose (500 mg) of the hormone therapy drug fulvestrant works better than the standard dose (250 mg) for postmenopausal women with advanced breast cancer that has continued to grow after previous hormone treatment. It involved 736 women and directly compared how long each dose kept the cancer from progressing. The goal was to see if the higher dose provides better disease control for this specific group of patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Casa Grande, Arizona, 85122, United States
Research Site

Fountain Valley, California, 92708, United States
Research Site

New Britain, Connecticut, 06052, United States
Research Site

Crystal River, Florida, 34429, United States
Research Site

Fort Lauderdale, Florida, 33308, United States
Research Site

Urbana, Illinois, 61801, United States
Research Site

Rosedale, Maryland, 21237, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

Kansas City, Missouri, 64131, United States
Research Site

St Louis, Missouri, 63141, United States
Research Site

Voorhees Township, New Jersey, 08043, United States
Research Site

Greenville, North Carolina, 27858, United States
Research Site

Pasadena, Texas, 77504, United States
Research Site

West Bend, Wisconsin, 53095, United States
Research Site

Brasschaat, 2930, Belgium
Research Site

Brussels, 1070, Belgium
Research Site

Brussels, 1090, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Hasselt, 3500, Belgium
Research Site

Liège, 4000, Belgium
Research Site

Turnhout, 2300, Belgium
Research Site

Barretos, 14784-400, Brazil
Research Site

Londrina, 86010-640, Brazil
Research Site

Porto Alegre, 91350-200, Brazil
Research Site

Recife, 50670-420, Brazil
Research Site

Salvador, 40170-070, Brazil
Research Site

São Paulo, 04039-001, Brazil
Research Site

Antofagasta, 1240000, Chile
Research Site

Santiago, 8380455, Chile
Research Site

Santiago, Chile
Research Site

Bogotá, Colombia
Research Site

Cali, Colombia
Research Site

Brno, 656 53, Czechia
Research Site

České Budějovice, 370 87, Czechia
Research Site

Pardubice, 520 03, Czechia
Research Site

Prague, 100 34, Czechia
Research Site

Prague, 128 08, Czechia
Research Site

Prague, 180 00, Czechia
Research Site

Tábor, 390 03, Czechia
Research Site

V Uvalu 84, 150 06, Czechia
Research Site

Nyíregyháza, 4400, Hungary
Research Site

Székesfehérvár, 8000, Hungary
Research Site

Szombathely, 9700, Hungary
Research Site

Ansārinagar, 110 029, India
Research Site

Bhopal, 462001, India
Research Site

Hyderabad, 500082, India
Research Site

Jaipur, 302013, India
Research Site

Kolkata, 700054, India
Research Site

Manipal, 576 104, India
Research Site

Marg Jaipur, 302004, India
Research Site

Mumbai, 400012, India
Research Site

Pune, 411001, India
Research Site

Trivandrum, 2417, India
Research Site

Vellore, 632004, India
Research Site

Aviano, 33081, Italy
Research Site

Bergamo, 24128, Italy
Research Site

Carpi, 41012, Italy
Research Site

Genova, 16132, Italy
Research Site

Prato, 59100, Italy
Research Site

Reggio Emilia, 42100, Italy
Research Site

Varese, 21100, Italy
Research Site

Floriana, VLT 14, Malta
Research Site

Mexico City, 06720, Mexico
Research Site

México, 01090, Mexico
Research Site

México, 14140, Mexico
Research Site

Bialystok, 15-027, Poland
Research Site

Lodz, 90-553, Poland
Research Site

Poznan, 61-878, Poland
Research Site

Ivanovo, 153040, Russia
Research Site

Kazan, Tatarstan, 420029, Russia
Research Site

Kazan, Tatarstan, 420111, Russia
Research Site

Krasnodar, 350040, Russia
Research Site

Lipetsk, 398005, Russia
Research Site

Moscow, 107005, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 121356, Russia
Research Site

Moscow, 59401, Russia
Research Site

Nizhny Novgorod, 603081, Russia
Research Site

Obninsk, 249020, Russia
Research Site

Ryazan, 390046, Russia
Research Site

Saint Petersburg, 191014, Russia
Research Site

Saint Petersburg, 197089, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Yaroslavl, 150054, Russia
Research Site

Bardejov, 08501, Slovakia
Research Site

Bratislava, 812 50, Slovakia
Research Site

Nitra, 949 01, Slovakia
Research Site

Trnava, 917 75, Slovakia
Research Site

A Coruña, 15006, Spain
Research Site

Madrid, 28040, Spain
Research Site

Málaga, 29010, Spain
Research Site

Oviedo, 33011, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Seville, 41013, Spain
Research Site

Cherkasy, 18009, Ukraine
Research Site

Dnipro, 49102, Ukraine
Research Site

Donetsk, 83092, Ukraine
Research Site

Kyiv, 03022, Ukraine
Research Site

Lviv, 79031, Ukraine
Research Site

Sumy, 40022, Ukraine
Research Site

Ternopil, 46023, Ukraine
Research Site

Uzhhorod, 88000, Ukraine
Research Site

Caracas, 1010, Venezuela
Research Site

Caracas, 1053, Venezuela
Research Site

Caracas, 1060, Venezuela

Conditions

Explore the condition pages connected to this study.

BREAST CANCER